Therapeutics was estimated to be worth US$ 4748 million in 2023 and is forecast to a readjusted size of US$ 6816.2 million by 2030 with a CAGR of 5.3% during the forecast period 2024-2030

Community Acquired Bacterial Pneumonia(CABP) Therapeutics - Market

Community Acquired Bacterial Pneumonia(CABP) Therapeutics includes a variety of drugs such as macrolides, fluoroquinolones, tetracyclines, and cephalosporins, which are used to treat bacterial infections.

The global market for Community Acquired Bacterial Pneumonia(CABP)

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Community Acquired Bacterial Pneumonia(CABP) Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Community Acquired Bacterial Pneumonia(CABP) Therapeutics by region & country, by Type, and by Application.

The Community Acquired Bacterial Pneumonia(CABP) Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Community Acquired Bacterial Pneumonia(CABP) Therapeutics.

Market Segmentation

Scope of Community Acquired Bacterial Pneumonia(CABP) Therapeutics - Market Report

Report Metric	Details
Report Name	Community Acquired Bacterial Pneumonia(CABP) Therapeutics - Market
Forecasted market size in 2030	US$ 6816.2 million
CAGR	5.3%
Forecasted years	2024 - 2030
Segment by Type:	Pleuromutilin Cephalosporin Glycylcycline Oxazolidinone Ketolide
Segment by Application	Hospital Pharmacy Retail Pharmacy Online Pharmacy
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, Pfizer, Paratek Pharmaceuticals,, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, Shionogi Inc., Allergan, Eagle Pharmaceutical Inc., Combioxin SA, Takeda, TiGenix
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Community Acquired Bacterial Pneumonia(CABP) Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Community Acquired Bacterial Pneumonia(CABP) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Community Acquired Bacterial Pneumonia(CABP) Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Community Acquired Bacterial Pneumonia(CABP) Therapeutics - Market size in 2030?

Ans: The Community Acquired Bacterial Pneumonia(CABP) Therapeutics - Market size in 2030 will be US$ 6816.2 million.

Who are the main players in the Community Acquired Bacterial Pneumonia(CABP) Therapeutics - Market report?

Ans: The main players in the Community Acquired Bacterial Pneumonia(CABP) Therapeutics - Market are Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, Pfizer, Paratek Pharmaceuticals,, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, Shionogi Inc., Allergan, Eagle Pharmaceutical Inc., Combioxin SA, Takeda, TiGenix

What are the Application segmentation covered in the Community Acquired Bacterial Pneumonia(CABP) Therapeutics - Market report?

Ans: The Applications covered in the Community Acquired Bacterial Pneumonia(CABP) Therapeutics - Market report are Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

What are the Type segmentation covered in the Community Acquired Bacterial Pneumonia(CABP) Therapeutics - Market report?

Ans: The Types covered in the Community Acquired Bacterial Pneumonia(CABP) Therapeutics - Market report are Pleuromutilin, Cephalosporin, Glycylcycline, Oxazolidinone, Ketolide

1 Market Overview

1.1 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product Introduction

1.2 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Size Forecast

1.3 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Trends & Drivers

1.3.1 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Industry Trends

1.3.2 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Drivers & Opportunity

1.3.3 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Challenges

1.3.4 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Players Revenue Ranking (2023)

2.2 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue by Company (2019-2024)

2.3 Key Companies Community Acquired Bacterial Pneumonia(CABP) Therapeutics Manufacturing Base Distribution and Headquarters

2.4 Key Companies Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product Offered

2.5 Key Companies Time to Begin Mass Production of Community Acquired Bacterial Pneumonia(CABP) Therapeutics

2.6 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Competitive Analysis

2.6.1 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Pleuromutilin

3.1.2 Cephalosporin

3.1.3 Glycylcycline

3.1.4 Oxazolidinone

3.1.5 Ketolide

3.2 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Type

3.2.1 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, by Type (2019-2030)

3.2.3 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital Pharmacy

4.1.2 Retail Pharmacy

4.1.3 Online Pharmacy

4.2 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Application

4.2.1 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, by Application (2019-2030)

4.2.3 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Region

5.1.1 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Region (2019-2024)

5.1.3 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Region (2025-2030)

5.1.4 Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, 2019-2030

5.2.2 North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, 2019-2030

5.3.2 Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, 2019-2030

5.4.2 Asia Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, 2019-2030

5.5.2 South America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, 2019-2030

5.6.2 Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value

6.3 United States

6.3.1 United States Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, 2019-2030

6.3.2 United States Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, 2019-2030

6.4.2 Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, 2019-2030

6.5.2 China Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.5.3 China Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, 2019-2030

6.6.2 Japan Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, 2019-2030

6.7.2 South Korea Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, 2019-2030

6.8.2 Southeast Asia Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, 2019-2030

6.9.2 India Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.9.3 India Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Nabriva Therapeutics

7.1.1 Nabriva Therapeutics Profile

7.1.2 Nabriva Therapeutics Main Business

7.1.3 Nabriva Therapeutics Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

7.1.4 Nabriva Therapeutics Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue (US$ Million) & (2019-2024)

7.1.5 Nabriva Therapeutics Recent Developments

7.2 Melinta Therapeutics

7.2.1 Melinta Therapeutics Profile

7.2.2 Melinta Therapeutics Main Business

7.2.3 Melinta Therapeutics Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

7.2.4 Melinta Therapeutics Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue (US$ Million) & (2019-2024)

7.2.5 Melinta Therapeutics Recent Developments

7.3 Wakunaga Pharmaceutical

7.3.1 Wakunaga Pharmaceutical Profile

7.3.2 Wakunaga Pharmaceutical Main Business

7.3.3 Wakunaga Pharmaceutical Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

7.3.4 Wakunaga Pharmaceutical Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue (US$ Million) & (2019-2024)

7.3.5 Forest Pharmaceuticals Recent Developments

7.4 Forest Pharmaceuticals

7.4.1 Forest Pharmaceuticals Profile

7.4.2 Forest Pharmaceuticals Main Business

7.4.3 Forest Pharmaceuticals Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

7.4.4 Forest Pharmaceuticals Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue (US$ Million) & (2019-2024)

7.4.5 Forest Pharmaceuticals Recent Developments

7.5 Pfizer, Paratek Pharmaceuticals,

7.5.1 Pfizer, Paratek Pharmaceuticals, Profile

7.5.2 Pfizer, Paratek Pharmaceuticals, Main Business

7.5.3 Pfizer, Paratek Pharmaceuticals, Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

7.5.4 Pfizer, Paratek Pharmaceuticals, Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue (US$ Million) & (2019-2024)

7.5.5 Pfizer, Paratek Pharmaceuticals, Recent Developments

7.6 Cumberland Pharmaceuticals Inc.

7.6.1 Cumberland Pharmaceuticals Inc. Profile

7.6.2 Cumberland Pharmaceuticals Inc. Main Business

7.6.3 Cumberland Pharmaceuticals Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

7.6.4 Cumberland Pharmaceuticals Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue (US$ Million) & (2019-2024)

7.6.5 Cumberland Pharmaceuticals Inc. Recent Developments

7.7 Theravance Biopharma

7.7.1 Theravance Biopharma Profile

7.7.2 Theravance Biopharma Main Business

7.7.3 Theravance Biopharma Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

7.7.4 Theravance Biopharma Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue (US$ Million) & (2019-2024)

7.7.5 Theravance Biopharma Recent Developments

7.8 Merck Sharp & Dohme Inc.

7.8.1 Merck Sharp & Dohme Inc. Profile

7.8.2 Merck Sharp & Dohme Inc. Main Business

7.8.3 Merck Sharp & Dohme Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

7.8.4 Merck Sharp & Dohme Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue (US$ Million) & (2019-2024)

7.8.5 Merck Sharp & Dohme Inc. Recent Developments

7.9 Cubist Pharmaceuticals LLC

7.9.1 Cubist Pharmaceuticals LLC Profile

7.9.2 Cubist Pharmaceuticals LLC Main Business

7.9.3 Cubist Pharmaceuticals LLC Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

7.9.4 Cubist Pharmaceuticals LLC Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue (US$ Million) & (2019-2024)

7.9.5 Cubist Pharmaceuticals LLC Recent Developments

7.10 Shionogi Inc.

7.10.1 Shionogi Inc. Profile

7.10.2 Shionogi Inc. Main Business

7.10.3 Shionogi Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

7.10.4 Shionogi Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue (US$ Million) & (2019-2024)

7.10.5 Shionogi Inc. Recent Developments

7.11 Allergan, Eagle Pharmaceutical Inc.

7.11.1 Allergan, Eagle Pharmaceutical Inc. Profile

7.11.2 Allergan, Eagle Pharmaceutical Inc. Main Business

7.11.3 Allergan, Eagle Pharmaceutical Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

7.11.4 Allergan, Eagle Pharmaceutical Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue (US$ Million) & (2019-2024)

7.11.5 Allergan, Eagle Pharmaceutical Inc. Recent Developments

7.12 Combioxin SA

7.12.1 Combioxin SA Profile

7.12.2 Combioxin SA Main Business

7.12.3 Combioxin SA Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

7.12.4 Combioxin SA Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue (US$ Million) & (2019-2024)

7.12.5 Combioxin SA Recent Developments

7.13 Takeda

7.13.1 Takeda Profile

7.13.2 Takeda Main Business

7.13.3 Takeda Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

7.13.4 Takeda Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue (US$ Million) & (2019-2024)

7.13.5 Takeda Recent Developments

7.14 TiGenix

7.14.1 TiGenix Profile

7.14.2 TiGenix Main Business

7.14.3 TiGenix Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

7.14.4 TiGenix Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue (US$ Million) & (2019-2024)

7.14.5 TiGenix Recent Developments

8 Industry Chain Analysis

8.1 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Industrial Chain

8.2 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Model

8.5.2 Sales Channel

8.5.3 Community Acquired Bacterial Pneumonia(CABP) Therapeutics Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Nabriva Therapeutics

Melinta Therapeutics

Forest Pharmaceuticals

Cumberland Pharmaceuticals Inc

Wakunaga Pharmaceutical

Pfizer, Paratek Pharmaceuticals,

Merck Sharp & Dohme Inc.

Cubist Pharmaceuticals LLC

Allergan, Eagle Pharmaceutical Inc.

Combioxin SA

List of Tables

Table 1. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Trends

Table 2. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Drivers & Opportunity

Table 3. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Challenges

Table 4. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Restraints

Table 5. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Community Acquired Bacterial Pneumonia(CABP) Therapeutics Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product Type

Table 9. Key Companies Time to Begin Mass Production of Community Acquired Bacterial Pneumonia(CABP) Therapeutics

Table 10. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Community Acquired Bacterial Pneumonia(CABP) Therapeutics as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Region (2019-2024) & (%)

Table 27. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, (2025-2030) & (US$ Million)

Table 31. Nabriva Therapeutics Basic Information List

Table 32. Nabriva Therapeutics Description and Business Overview

Table 33. Nabriva Therapeutics Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

Table 34. Revenue (US$ Million) in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business of Nabriva Therapeutics (2019-2024)

Table 35. Nabriva Therapeutics Recent Developments

Table 36. Melinta Therapeutics Basic Information List

Table 37. Melinta Therapeutics Description and Business Overview

Table 38. Melinta Therapeutics Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

Table 39. Revenue (US$ Million) in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business of Melinta Therapeutics (2019-2024)

Table 40. Melinta Therapeutics Recent Developments

Table 41. Wakunaga Pharmaceutical Basic Information List

Table 42. Wakunaga Pharmaceutical Description and Business Overview

Table 43. Wakunaga Pharmaceutical Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

Table 44. Revenue (US$ Million) in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business of Wakunaga Pharmaceutical (2019-2024)

Table 45. Wakunaga Pharmaceutical Recent Developments

Table 46. Forest Pharmaceuticals Basic Information List

Table 47. Forest Pharmaceuticals Description and Business Overview

Table 48. Forest Pharmaceuticals Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

Table 49. Revenue (US$ Million) in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business of Forest Pharmaceuticals (2019-2024)

Table 50. Forest Pharmaceuticals Recent Developments

Table 51. Pfizer, Paratek Pharmaceuticals, Basic Information List

Table 52. Pfizer, Paratek Pharmaceuticals, Description and Business Overview

Table 53. Pfizer, Paratek Pharmaceuticals, Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

Table 54. Revenue (US$ Million) in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business of Pfizer, Paratek Pharmaceuticals, (2019-2024)

Table 55. Pfizer, Paratek Pharmaceuticals, Recent Developments

Table 56. Cumberland Pharmaceuticals Inc. Basic Information List

Table 57. Cumberland Pharmaceuticals Inc. Description and Business Overview

Table 58. Cumberland Pharmaceuticals Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

Table 59. Revenue (US$ Million) in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business of Cumberland Pharmaceuticals Inc. (2019-2024)

Table 60. Cumberland Pharmaceuticals Inc. Recent Developments

Table 61. Theravance Biopharma Basic Information List

Table 62. Theravance Biopharma Description and Business Overview

Table 63. Theravance Biopharma Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

Table 64. Revenue (US$ Million) in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business of Theravance Biopharma (2019-2024)

Table 65. Theravance Biopharma Recent Developments

Table 66. Merck Sharp & Dohme Inc. Basic Information List

Table 67. Merck Sharp & Dohme Inc. Description and Business Overview

Table 68. Merck Sharp & Dohme Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

Table 69. Revenue (US$ Million) in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business of Merck Sharp & Dohme Inc. (2019-2024)

Table 70. Merck Sharp & Dohme Inc. Recent Developments

Table 71. Cubist Pharmaceuticals LLC Basic Information List

Table 72. Cubist Pharmaceuticals LLC Description and Business Overview

Table 73. Cubist Pharmaceuticals LLC Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

Table 74. Revenue (US$ Million) in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business of Cubist Pharmaceuticals LLC (2019-2024)

Table 75. Cubist Pharmaceuticals LLC Recent Developments

Table 76. Shionogi Inc. Basic Information List

Table 77. Shionogi Inc. Description and Business Overview

Table 78. Shionogi Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

Table 79. Revenue (US$ Million) in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business of Shionogi Inc. (2019-2024)

Table 80. Shionogi Inc. Recent Developments

Table 81. Allergan, Eagle Pharmaceutical Inc. Basic Information List

Table 82. Allergan, Eagle Pharmaceutical Inc. Description and Business Overview

Table 83. Allergan, Eagle Pharmaceutical Inc. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

Table 84. Revenue (US$ Million) in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business of Allergan, Eagle Pharmaceutical Inc. (2019-2024)

Table 85. Allergan, Eagle Pharmaceutical Inc. Recent Developments

Table 86. Combioxin SA Basic Information List

Table 87. Combioxin SA Description and Business Overview

Table 88. Combioxin SA Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

Table 89. Revenue (US$ Million) in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business of Combioxin SA (2019-2024)

Table 90. Combioxin SA Recent Developments

Table 91. Takeda Basic Information List

Table 92. Takeda Description and Business Overview

Table 93. Takeda Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

Table 94. Revenue (US$ Million) in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business of Takeda (2019-2024)

Table 95. Takeda Recent Developments

Table 96. TiGenix Basic Information List

Table 97. TiGenix Description and Business Overview

Table 98. TiGenix Community Acquired Bacterial Pneumonia(CABP) Therapeutics Products, Services and Solutions

Table 99. Revenue (US$ Million) in Community Acquired Bacterial Pneumonia(CABP) Therapeutics Business of TiGenix (2019-2024)

Table 100. TiGenix Recent Developments

Table 101. Key Raw Materials Lists

Table 102. Raw Materials Key Suppliers Lists

Table 103. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Downstream Customers

Table 104. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Distributors List

Table 105. Research Programs/Design for This Report

Table 106. Key Data Information from Secondary Sources

Table 107. Key Data Information from Primary Sources

Table 108. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Product Picture

Figure 2. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 4. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Report Years Considered

Figure 5. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Community Acquired Bacterial Pneumonia(CABP) Therapeutics Revenue in 2023

Figure 7. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Pleuromutilin Picture

Figure 9. Cephalosporin Picture

Figure 10. Glycylcycline Picture

Figure 11. Oxazolidinone Picture

Figure 12. Ketolide Picture

Figure 13. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 14. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value Market Share by Type, 2023 & 2030

Figure 15. Product Picture of Hospital Pharmacy

Figure 16. Product Picture of Retail Pharmacy

Figure 17. Product Picture of Online Pharmacy

Figure 18. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 19. Global Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value Market Share by Application, 2023 & 2030

Figure 20. North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 21. North America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 22. Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 23. Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 24. Asia Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 25. Asia Pacific Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 26. South America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 27. South America Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 28. Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 29. Middle East & Africa Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 30. Key Countries/Regions Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value (%), (2019-2030)

Figure 31. United States Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 32. United States Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 33. United States Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 34. Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 35. Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 36. Europe Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 37. China Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 38. China Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 39. China Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 40. Japan Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 41. Japan Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 42. Japan Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 43. South Korea Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 44. South Korea Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 45. South Korea Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 46. Southeast Asia Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 47. Southeast Asia Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 48. Southeast Asia Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 49. India Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 50. India Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 51. India Community Acquired Bacterial Pneumonia(CABP) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 52. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Industrial Chain

Figure 53. Community Acquired Bacterial Pneumonia(CABP) Therapeutics Manufacturing Cost Structure

Figure 54. Channels of Distribution (Direct Sales, and Distribution)

Figure 55. Bottom-up and Top-down Approaches for This Report

Figure 56. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-26V13549

Mon Nov 11 00:00:00 UTC 2024

Add to Cart

Pharmaceutical Grade Sodium Hyaluronate - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-17N14065

Mon Nov 11 00:00:00 UTC 2024

Add to Cart

Pharmaceutical Fluid Bed System - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-6Q14792

Fri Nov 08 00:00:00 UTC 2024

Add to Cart

Medical Microbial Incubators - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-30W13258

Thu Nov 07 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Community Acquired Bacterial Pneumonia(CABP) Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: October 2024

Report Code: QYRE-Auto-39N14041

Community Acquired Bacterial Pneumonia(CABP) Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

FEATURED COMPANIES

Community Acquired Bacterial Pneumonia(CABP) Therapeutics - Market Size

Community Acquired Bacterial Pneumonia(CABP) Therapeutics - Market

Report Scope

Scope of Community Acquired Bacterial Pneumonia(CABP) Therapeutics - Market Report

Chapter Outline

FAQ for this report

What is the Community Acquired Bacterial Pneumonia(CABP) Therapeutics - Market size in 2030?

Who are the main players in the Community Acquired Bacterial Pneumonia(CABP) Therapeutics - Market report?

What are the Application segmentation covered in the Community Acquired Bacterial Pneumonia(CABP) Therapeutics - Market report?

What are the Type segmentation covered in the Community Acquired Bacterial Pneumonia(CABP) Therapeutics - Market report?

FEATURED COMPANIES

RELATED REPORTS